arrow
D

Douglas R. Adkins

siteman cancer center
H指数:53
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neoadjuvant and Adjuvant Pembrolizumab (Pembro) Plus Standard of Care (SOC) in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC): Postoperative Risk Subgroup Analysis of KEYNOTE-689

新辅助和辅助帕博利珠单抗(Pembro)联合标准治疗(SOC)在可切除局部晚期头颈鳞状细胞癌(LA HNSCC)中的应用:KEYNOTE-689研究术后风险亚组分析

2025-10-140
PRE
Long-Term Outcomes of Patients With HPV plus Unknown Primary Squamous Cell Carcinoma Treated With Transoral Surgery

HPV阳性且原发灶不明的口咽鳞状细胞癌患者经经口手术治疗的长期预后

2025-10-010
PRE
In vivo CRISPR screening in head and neck cancer reveals Uchl5 as an immunotherapy target

体内CRISPR筛选在头颈癌中揭示Uchl5作为免疫治疗靶点

2025-09-290
OAAI
Establishing an integrated approach to head and neck cancer treatment and prevention: The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center Model

建立头颈癌治疗与预防的整合方法:Robert Ebert和Greg Stubblefield头颈肿瘤中心模式

2025-08-090
OA
Contralateral Neck Recurrence Rates After Ipsilateral Neck Adjuvant Radiation in Head and Neck Carcinomas with a Pathologically Negative Contralateral Neck

病理阴性对侧颈部头颈癌在患侧颈部辅助放疗后的对侧颈部复发率

2025-06-020
OAAI
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study

通过分子改变选择的实体瘤患者的sitratinib: Ib期研究的结果

2024-11-080
OAAI
Petosemtamab plus pembrolizumab vs. pembrolizumab alone for first-line (1L) treatment of recurrent/metastatic (r/m) PD-L1epositive head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial

Petosemtamab plus pembrolizumab与pembrolizumab单药治疗PD-L1阳性复发/转移性(r/m)头颈鳞状细胞癌(HNSCC)的一线(1L)治疗:一项随机、开放标签、III期试验

2024-09-010
PRE
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer
2023-09-2925
OA
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
2023-06-2014
OAAI
Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer
2023-03-2227
OAAI
Head and Neck Cancers, Version 1.2022 Featured Updates to the NCCN Guidelines

头颈癌,1.2022版更新了NCCN指南

2022-03-01255
OA